A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration
A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration since planting roots in the Queen City, and officials said the deal will help fuel faster international growth.
Orange Grove Bio, a preclinical drug investment and development firm based at University of Cincinnati’s 1819 Innovation Hub, announced a new partnership Tuesday with SV Investment, a Seoul, Korea-based venture capital and private equity firm. The companies said the partnership will allow them to collaborate on jointly sourcing and developing new therapeutics in the U.S. and East Asia.
Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration
Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration to Strengthen Biotech Ecosystem and Support Development and Commercialization of Novel Therapeutics The following excerpt was taken from Globenewswire– continue reading here. Orange Grove Bio, a drug investment and development firm, today announced the establishment of a strategic collaboration with the Magnuson… Continue reading Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration
March 16, 2022
Orange Grove Bio and Cincinnati Children’s Hospital Medical Center Establish Collaboration
Orange Grove Bio, a preclinical drug investment and development firm, and Cincinnati
November 4, 2021
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area The following excerpt was taken from Cincinnati Enquirer — continue reading here. Orange Grove Bio, a venture capital firm that invests mainly in therapeutic drug companies, is moving its headquarters from the New York City “Orange Grove Bio, a venture capital firm that invests… Continue reading Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
March 8, 2021
Cronicle Tech News
Cronicle Tech News The following was taken from the Cronicle written by Lauren K. Cowan. Check out the original piece here: https://cronicle.press/2021/03/08/ann-arbors-asalyxa-bio-raises-2-million-to-start-clinical-trials-for-neutrophil-targeting-drug-delivery-tech/ Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities Asalyxa Bio, Inc., a biopharmaceutical startup developing nano-engineered, immune cell-targeted therapeutics, just announced the closing of… Continue reading Cronicle Tech News
October 6, 2021
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry We are excited to announce our portfolio company, Ipinovyxbio‘s, launch! The following was taken from Fierce Biotech–read it here or continue below! “With a focus on autoimmune and inflammatory diseases, IpiNovyx Bio closed a $10 million seed financing round” “Eli Lilly is among the… Continue reading Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry
July 5, 2022
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend… Continue reading Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
January 25, 2020
How to Invest in Biotech Series – Phases, Stages, and Pitfalls
Emily Whitehead was 5 years old when she was diagnosed with acute lymphoblastic leukemia… Her cancer was resistant to traditional treatments and her prognosis was poor. In a final effort to save their daughter, her parents enrolled her in a clinical trial study at Children’s Hospital of Philadelphia for a new type of therapy called… Continue reading How to Invest in Biotech Series – Phases, Stages, and Pitfalls
October 6, 2021
IpiNovyx Bio closes $10 million seed financing round
IpiNovyx Bio closes $10 million seed financing round The below is an excerpt taken from EndPoints News about our portfolio company, Ipinovyx Bio. The following excerpt was taken from EndPonts News — continue reading here. “With a focus on autoimmune and inflammatory diseases, IpiNovyx Bio closed a $10 million seed financing round “With a focus… Continue reading IpiNovyx Bio closes $10 million seed financing round
November 17, 2021
New Partnership Continues Pitt’s Turn Toward Commercializing Research
New Partnership Continues Pitt’s Turn Toward Commercializing Research The following excerpt was taken from Pittsburgh Post-Gazette — continue reading here. An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies “An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies targeting… Continue reading New Partnership Continues Pitt’s Turn Toward Commercializing Research
Prev